Treatment of Cytomegalovirus Infection or Disease in Solid Organ Transplant Recipients with Valganciclovir
Authors:
- Jacques FellayJFJacques Fellay
- Jean-Pierre VenetzJVJean-Pierre Venetz
- Manuel PascualMPManuel Pascual
- John-David AubertJAJohn-David Aubert
- Charles SeydouxCSCharles Seydoux
- Pascal Ra MeylanPMPascal Ra Meylan
Open Access
- 8 June 2005
- journal article
- Published by Elsevier in American Journal of Transplantation
- Vol. 5 (7) , 1781-1782
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Canadian Society of Transplantation Consensus Workshop on Cytomegalovirus Management in Solid Organ Transplantation Final ReportAmerican Journal of Transplantation, 2005
- Kinetics of Cytomegalovirus Load Decrease in Solid‐Organ Transplant Recipients after Preemptive Therapy with ValganciclovirThe Journal of Infectious Diseases, 2005
- CytomegalovirusAmerican Journal of Transplantation, 2004
- Treatment of Cytomegalovirus Disease with Valganciclovir in Renal Transplant Recipients: A Single Center ExperienceTransplantation, 2004
- Determinants of protracted cytomegalovirus infection in solid-organ transplant patients1Transplantation, 2002
- A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus RetinitisNew England Journal of Medicine, 2002
- Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hostsExpert Opinion on Investigational Drugs, 2001